Enyo Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, dedicated to developing innovative therapeutics targeting fibro-inflammatory pathways in kidney and metabolic diseases. The company's lead candidate, Vonafexor (EYP001), is a synthetic, non-steroidal, non-bile acid agonist of the farnesoid X receptor (FXR), a nuclear receptor pivotal in regulating bile acid metabolism, inflammation, and fibrosis. It is currently in Phase 2 development for rare kidney disease Alport Syndrome and Chronic Kidney Diseases (CKD). ENYO Pharma’s lead compound Vonafexor displays excellent profile in clinical studies.